Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis

By afschroeder • December 6, 2025

Armstrong AW, Warren RB, Sofen H, Spelman L, Linaberry M, Becker B, Jou YM, Daamen C, Kimball AB. Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis. Dermatol Ther (Heidelb). 2025 Dec 5. doi: 10.1007/s13555-025-01606-9. Epub ahead of print. PMID: 41350512.

Tags: clinical trials, Dermatology, deucravacitinib, Olive View DoM, psoriasis, Psoriasis treatment, Publications, Tyrosine kinase 2 inhibitor

Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT

Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, López Pinto JM, Wixted K, Thaçi D. Bimekizumab Impact[...]

Differences in Prescription Patterns Among Various Physician Specialties for Patients with Chronic Spontaneous Urticaria

Chou P, Ma E, Roberts A, Jeong C, Katz A, Yan MJ, Johnsen N, Nong Y, Yee M, Armstrong A. Differences in Prescription Patterns Among[...]

Laboratory monitoring in patients with moderate to severe plaque psoriasis

Fenkel JM, Osborne JA, Armstrong AW, Strober B, Stein Gold L, Cameron M, Lebwohl M. Laboratory monitoring in patients with moderate to severe plaque psoriasis.[...]